BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with Progenics Pharmaceuticals (Nasdaq:PGNX). The milestone was triggered by Progenics’ initiation of a phase I clinical trial with its prostate-specific membrane antigen (PSMA)-targeted ADC for patients with hormone-refractory prostate cancer.
